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Abstract 
We have investigated sialidase activities in transformed rat 3Y 1 cells of different metastatic potential. Only lysosome-type sialidase was apparent 
in the particulate fractions of 3Yl cells and their transformants. As compared with control 3Y1 cells, src-transformed cells exhibited decreased 
sialidase activity, and v-for transfer to these latter induced even more severe decrease in the sialidase activity with acquisition of high lung metastatic 
ability. Various lysosomal enzymes other than sialidase were hardly affected by the transformation. Sialic acid transfer to N-linked glycoproteins 
was slightly elevated in the transformants, but not in parallel with their metastatic potential. 
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1. Introduction 
Cell surface carbohydrates are known to undergo var- 
ious alterations during neoplasia. The changes generally 
involve glycoproteins expressed on tumor cell surface 
with increased branching of complex-type N-glycans, in- 
creased polylactosaminoglycan chains and increased sia- 
lylation [l-5], which are correlated not only with tumo- 
rigenicity but also with elevated metastatic potential 
[6,7]. In particular, the alterations in sialylation have 
been proposed to be intimately associated with invasive- 
ness and metastatic ability [4,6,8,9]. To elucidate how 
such aberrant sialylation occurs in cancer cells, we have 
been studying sialidase and sialyltransferase in rat 
hepatoma [lo-121 and other tumor models [13]. We are 
now focusing on the enzyme studies in relation to inva- 
siveness and metastasis. 
Our previous studies on rat sialidases demonstrated 
four enzyme types differing in subcellular distribution 
and in catalytic and immunological properties. Located 
in the lysosomal matrix [14], cytosol [15] lysosomal mem- 
brane and plasma membrane [16], they are altered quan- 
titatively in hepatocarcinogenesis [lo] and in phorbol 
ester-induced malignant transformation of mouse epi- 
dermal JB6 cells [13]. We also found that Gal/R- 
4GlcNAca 2-6 sialyltransferase activity was selectively 
increased in hepatomas [11,12]. Based on these results, 
we have determined the activity levels of sialidase and 
*Corresponding author. Fax: (81) (22) 381-l 195. 
Abbreviations: NeuAc, N-acetylneuraminic a id; 4MU-NeuAc, 4-meth- 
ylumbelhferyl-a-o-N-acetyl-neuraminic acid; Lac-cer, lactosylcer- 
amide. 
sialyltransferase of transformed rat fibroblast 3Y 1 cell 
lines of different metastatic potential. The transformed 
cells were found to demonstrate much more prominent 
alteration of sialidase than sialyltransferase activities. 
2. Materials and methods 
2. I. Materials 
4MU-NeuAc was purchased from Nakarai (Kyoto, Japan). GM3 
labeled in the NeuAc moiety was synthesized enzymatically from lacto- 
sylceramide and CMP-NeuAc as described previously [17]. CMP- 
[“‘C]NeuAc was obtained from New England Nuclear (Boston, MA) 
and diluted with cold CMP-NeuAc from Sigma (St. Louis, MO) to give 
a final specific activity of 2.5 Ci/mol. The sources of gangliosides and 
glycoproteins used as substrates for sialidase and sialyltransferase as- 
says were described elsewhere [I 1,151. 
2.2. Cells 
Cells were routinely cultivated in Dulbecco’s modified Eagle’s me- 
dium containing 10% fetal bovine serum in 10% CO2 and 90% air. 
SR-3Y1-2 is tumorgenic but low metastatic ell line established by 
infection of a normal rat fibroblast cell line, 3Yl-B clone l-6 with the 
Schmidt-Ruppin D strain Rous sarcoma virus [18]. The fos-SR-3Yl- 
202,203 and 205 are highly metastatic ell lines established by transfer 
of pFBJ-2 plasmid containing proviral v-fos DNA and pSV2-neo into 
SR-3Y I-2 [19]. v-fos transfer enhances lung metastasis n relation to an 
increase in invasiveness [20]. Cells harvested prior to confluency were 
rinsed in culture flasks with phosphate-buffered saline, scraped out with 
a rubber policeman, and collected at 600 x g for 5 min. The packed cells 
were washed with phosphate-buffered saline and sonicated on ice in 
9 vols. of ice-cold 0.25 M sucrose containing 1 mM EDTA 2 times each 
for 15 min at the maximum speed. The mixture was then centrifuged 
at 600 x g for 10 min and the supernatant at 105,000 x g for 60 min at 
4°C. The resultant supernatant was used as the cytosolic fraction, and 
the pellet suspended in 9 ~01s. of the sucrose solution was used as the 
particulate fraction. The fractions were either used immediately for the 
assays or kept frozen at -70°C. Protein was determined by the method 
of Bradford [21]. 
2.3. Determination of sialic acid 
Cells (1 x 100 were incubated with 0.02 units of Arthrobacter ureafa- 
ciens sialidase in I ml of 0.01 M sodium phosphate buffer (pH 6.5) 
0014-579319487.00 0 1994 Federation of European Biochemical Societies. All rights reserved. 
SSDI 0014-5793(94)00682-L 
256 7: Miyagi et ul. I FEBS Letters 349 (1994) 285 259 
containing 0.15 M NaCl at 37°C for 1-2 h. After centrifugation, the 
supematant was assayed for sialic acid by the thiobarbituric acid 
method of Aminoff [22]. Viability remained over 90%. For total sialic 
acid determination, cells were treated in 0.05 M H,SO, for 60 min at 
80°C and centrifuged. The resulting supernatant was assayed for sialic 
acid as above. 
2.4. Sialidase assay 
4MU-NeuAc and “‘C-labeled GM3 were routinely used as substrate, 
since 4MU-NeuAc was previously found to be an appropriate substrate 
for intralysosomal and cytosolic sialidases and GM3 for membrane- 
associated sialidases. The assays were performed under the optimal 
conditions as follows. When 4MU-NeuAc was the substrate, the assay 
mixture contained 60 nmol of the substrate, 5 pmol of sodium acetate 
buffer (pH 4.7) 100 pg of bovine serum albumin and particulate frac- 
tions (20-60 fig protein) in a final volume of 0.1 ml. For the assay of 
cytosolic sialidase, sodium acetate buffer was replaced by sodium ca- 
codylate buffer (pH 6.0). The incubation was conducted at 37°C for l-2 
h and terminated by the addition of 0.25 M glycine-NaOH (pH 10.4). 
4-Methyl-umbelliferone released was determined fluorometrically as 
described previously [15]. With [“‘C]GM3 as substrate the assay mixture 
was composed of 10 nmol of the substrate, 5 pmol of sodium acetate 
(pH 4.7) 100 pg of bovine serum albumin, 50 pug of sodium deoxycho- 
late and enzyme in 0.1 ml. After incubation at 37°C for 60 min, the 
radioactivity in the trichloroacetic acid-soluble fraction was determined 
[17]. When other substrates were employed, sialic acid released was 
determined after AGlX-2 column chromatography. 
2.5. Sialyltransjkzse assay 
Sialyltransferase activities were determined under the optimal condi- 
tions described below. When asialo- (AS-) glycoproteins were accep- 
tors, the assay mixture contained 0.04 pmol of CMP-f?]NeuAc, 50- 
100 prnol (expressed in terms of acceptor site) of acceptor, 5 pmol of 
sodium cacodvlate (DH 6.3). 100 ua of Triton X-100 and enzyme (20-60 
pug) in 0.1 ml. After incubation at>7”C for l-2 h, protein-bound radi- 
oactivity was determined as described previously [l I]. With glycolipid 
as acceptor, the assay mixture was the same as for glycoprotein accep- 
tors except 20-50,~~rnol of acceptor was used. The reaction product was 
measured by counting the radioactivity incorporated into the corre- 
sponding area co-migrating with a standard in a thin layer plate [I 21. 
2.6. Other assays 
&Galactosidase. /?-N-acetylglucosaminidase nd a-fucosidase were 
assayed with the respective 4MUglucosides as described [17]. Assays 
of acid phosphatase and cathepsin D were also conducted as described 
previously [14]. 
3. Results 
Table 1 shows that total sialic acid and sialidase-re- 
leasable sialic acid contents were increased by transfor- 
mation with V-SK and v-j&s. A transformed rat fibroblast 
clone (SR-3Yl-2) induced by infection with Rous sar- 
Table I 
Sialic acid contents of 3Yl cells and their transformants 
Cell lines 
3Yl 
SR-3Yl-2 
fos-SR-3Y I-202 
fos-SR-3Y l-203 
Total Sialidase-accessible 
sialic acid sialic acid 
@g/mg protein) (,@mg protein) 
13.41 f 1.50 3.42 + 0.22 
24.32 f 2.31* 6.25 k 0.16** 
24.31 f 3.33* 6.28 f 0.45** 
26.20 f 2.15* 5.67 + 0.12** 
Values are means f S.D. of three batches of cells. 
Significant difference from 3Y 1: *P < 0.01; **P < 0.001. 
Table 2 
Sialidase activities of 3Y I cells and their transformants 
Substrate 
Cell lines 
4MU-NeuAc [‘4C]-GM3 
(mmol/h/pg protein) (mmol/h/pg protein) 
3Y1 92.5 I? 12.5 0.21 f 0.05 
SR-3Y l-2 31.2 + 2.4* N.D. 
fos-SR-3Y I-202 11.4 + 3.6**,*** 0.16 + 0.10 
fos-SR-3Y l-203 10.5 + 6.1**,*** N.D. 
fos-SR-3Y l-205 18.7 + 2.7+*,*** N.D. 
Values are means f S.D. of four different batches of cells. Significant 
difference from 3Yl (*P < 0.025; **P < 0.01) and from SR-3YlL2 
(***P < 0.01); N.D. = not detected. 
coma virus, possessed twice the amount in the control rat 
fibroblast cell line (3Yl clone). However, augmentation 
of spontanous lung metastasis by v-jiis transfer into SR- 
3Yl-2 did not further increase the sialic acid contents as 
evidenced by the results for fos-SR-3Yl-202 and -203. 
When the 3Y 1 cells and their transformants were assayed 
for sialidase activity using 4MU-NeuAc or GM3 as sub- 
strates, they exhibited sialidase activity toward 4MU- 
NeuAc but little toward GM3 at pH 4.7 in the particulate 
fractions. The cytosolic fraction could not hydrolyze any 
of these substrates at either pH 4.7 or 6.0. Sialidase in the 
particulate fractions hydrolyzed sialyllactose and fetuin 
glycopeptides as well as 4MU-NeuAc at pH 4.7; the 
relative rates of hydrolysis were 45%, 40% and lOO%, 
respectively. Glycoproteins were hardly hydrolyzed and 
gangliosides practically failed as substrates even in the 
presence of detergents uch as Triton X-100 or sodium 
cholate. When the cell homogenates were fractionated 
according to de Duve et al. [23] and the resulting frac- 
tions were assayed with 4-MU-NeuAc as substrate, more 
than 60% of this acidic sialidase activity was found in the 
lysosomal/mitochondrial fraction, in which as much ac- 
tivity of acid phosphatase, a marker enzyme for lyso- 
somes, was present. These results indicate that 3Y1 cells 
and their transformants possess only a lysosomal matrix- 
type sialidase, which was previously characterized as one 
of the four types of rat liver sialidase able to hydrolyze 
only low molecular weight substrates. As compared with 
the sialidase activity of control 3Y1 cells, the activity 
levels were markedly reduced in the transformants 
(Table 2). This was more pronounced in highly metas- 
tatic cells, fos-SR-3Y 1, than in those with low metastatic 
potential, SR-3Yl-2. To determine if the low levels of 
sialidase activity in the transformants were due to the 
presence of any inhibitor, the particulate fractions of 
transformed cells were added to that of control 3Y 1 cells, 
and the combined fractions measured for sialidase activ- 
ity. The combined fractions showed essentially equiva- 
lent values to the sums of the two data obtained individ- 
I: Miyagi et al. IFEBS Letters 349 (1994) 255-259 257 
Table 3 
Low levels of sialidase activity in transformants are not due to the 
presence of an inhibitor 
Particulate fraction Sialidase activity 
(nmol/h) 
3Y1 7.4 
SR-3Y1-2 (2) 1.7 
fos-SR-3Y I-202 (3) 0.93 
(I) + (2) 8.4 
(I) + (3) 7.8 
Sialidase activity was assayed at pH 4.7 in the particulate fraction(s) of 
3Y I cells and/or their transformants. Values are means of two experi- 
ments. 
ually as shown in Table 3, indicating that a special inhib- 
itor may not be involved in decrease of sialidase activity 
in the transformants. As the sialidases of the 3Yl cells 
and their transformants were suggested to be of ly- 
sosome-type, we examined whether several ysosomal en- 
zymes other than sialidase might also be altered by the 
oncogenic transformation (Table 4). Unlike the sialidase, 
the activities of four glycosidases and cathepsin D were 
hardly affected. Although decrease in some of the en- 
zyme activities in v-fos transferred cells was appreciable, 
in all cases it occurred to a much lesser extent than for 
sialidase. We also compared the activity levels of sia- 
lyltransferases between control 3Y 1 cells and their trans- 
formants using glycoprotein and glycolipid acceptors as 
shown in Fig. 1. The activity toward asialo-orosomucoid 
was somewhat increased in the transformants while little 
changes were observed in the activities with two asialo- 
submaxillary mucins and asialo-transferrin as acceptors. 
The sialyltransferases responsible for ganglioside forma- 
tion were rather reduced in activity by the transforma- 
tion. 
4. Discussion Table 4 
The present study revealed that oncogenic transforma- 
tion of rat 3Yl cells causes alterations of sialidase and 
sialyltransferase activities accompanied by an increase of 
sialic acid contents. The most striking findings were that 
transformed cells demonstrate severely reduced ly- 
sosome-type sialidase activity and that acquisition of 
highly metastatic potential with v-fos transfer was associ- 
ated with further remarkable decrease in sialidase activ- 
ity. Interestingly, this seems to be specific to sialidase 
among lysosomal enzymes. Total sialic acid as well as 
surface sialic acid contents were higher in the trans- 
formed cells than in control cells, but did not correlate 
with metastatic potential. This may imply that only the 
sialic acids of particular sialoglycoconjugates are in- 
volved in metastasis. The transformed cells exhibited to 
some degree increased sialyltransfer to asialo-orosomu- 
coid containing tri- and tetra-antennary complex-type 
chains. On the other hand, sialyltransfer to glycolipid 
acceptor was rather decreased. These data suggest hat 
increase in sialic acid bound to N-linked glycoprotein 
would occur with a concomitant decrease in that bound 
to glycolipid. Such a tendency was also shown previously 
for phorbol ester-induced transformants of JB6 mouse 
epidermal cells, characterized ecreased lysosomal siali- 
dase activity and increased sialyltransfer to N-linked 
glycoproteins [131. 
High metastatic potential of fos-SR-3Y 1 cells was ear- 
lier described to be closely related to high invasiveness, 
in association with augmentation of cell motility [20]. 
Consequently, their metabolic shift to an increased sialic 
acid density, at least of some sialoglycoproteins responsi- 
ble, may bring about the enhanced metastasis, especially 
invasiveness. This is also consistent with other work de- 
monstrating good correlations between sialic acid con- 
tents and invasiveness [4,6,8,9]. We have further found 
that BL6 cells, a high invasive variant of B16 melanoma 
cells, have higher levels of sialyltransferase activity than 
cells of low invasiveness, although in that case sialidase 
activity was hardly affected (unpublished data). 
SK gene products most likely act at a post-transla- 
tional level such as phosphorylation, whereas fos gene 
products are involved in many cellular events due to their 
trans-acting transcription function [24]. It is at present 
far from understood how expression of src and fos genes 
is related to alterations in sialidase and sialyltransferase 
and how these oncogenes modify sialidase activity selec- 
tively among various lysosomal enzymes. Investigations 
of whether transfection of a recently cloned rat sialidase 
gene [25] into fos-SR-SY 1 cell might reduce their metas- 
tatic potential are now under way. 
Glycosidase and cathepsin D activities of 3Y 1 cells and their transfor- 
mants 
3Yl SR3Y l-2 fos-SR-3Y I- 
202 
Sialidase 84.4 
(nmoVh/mg protein) 
29.1 12.6 
/%Galactosidase 
/?-N-Acetyl- 
glucosaminidase 
Fucosidase 
Acid phosphatase 
15.1 
24.9 
10.9 
149.6 
(nmol/min/mg protein 
18.6 11.4 
28.3 22.5 
9.7 8.3 
138.8 120.4 
@g/min/mg protein) 
Cathepsin 25.7 26.7 19.5 
Values are means of two experiments. 
258 7: Miyagi et al. I FEBS Letters 349 (1994) 255-259 
AS-orosomucoid AS-transferrin AS-porcine mucin AS-bovine mucin 
(b) 
glycoprotein acceptors 
Lac-cer GM3 GM1 
glycolipid acceptors 
GDla 
Fig. 1. Sialyltransferase activities toward glycoprotein (a) and glycolipid (b) acceptors in 3Y 1 cells and their transformants. Asialo- (AS-) orosomucoid, 
-transferrin, -bovine submaxillary mucin were prepared by mild acid hydrolysis (0.1 N H-SO, at 80°C for 1 h) and AS-porcine submaxillary mucin 
by treating with 1 N H,SO, at 70°C for 3 h to remove sialic acid and fucose. Activities are meanstS.D. of three batches of cells. Significant differncc 
from 3Y1 (*P < 0.05, **P < 0.01). q = 3Y1; q = SR-3Y1-2; @ = fos-SR-3Yl. 
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